美国食品药品监督管理局批准摘要:纳武利尤单抗联合铂类双药化疗用于可切除非小细胞肺癌新辅助治疗
2022年3月4日,美国食品药品监督管理局(FDA)批准纳武利尤单抗联合铂类双药化疗用于可切除非小细胞肺癌(NSCLC)的新辅助治疗。该批准基于CheckMate 816试验,358例可切除NSCLC患者随机接受纳武利尤单抗联合化疗或单纯化疗3周期后手术;主要终点无事件生存期(EFS)的风险比(HR)为0.63(95%CI 0.45-0.87;P=0.0052),支持该批准。
要点
- FDA于2022年3月4日批准纳武利尤单抗联合铂类双药化疗用于可切除NSCLC新辅助治疗。
- CheckMate 816试验中,纳武利尤单抗联合化疗组中位EFS为31.6个月,单纯化疗组为20.8个月,HR=0.63。
- 总生存期(OS)HR为0.57(95%CI 0.38-0.87;P=0.0079),未跨越显著性边界0.0033。
核心结论
- 该批准基于CheckMate 816试验中EFS具有统计学显著和临床意义的改善,且无OS受损证据,对患者接受手术及手术时机或手术结局无负面影响。
研究设计与样本
- 基于国际、多区域、活性对照试验CheckMate 816,随机分配358例可切除NSCLC患者(依据美国癌症联合委员会第七版分期为IB期(≥4 cm)至IIIA期(N2))。
- 患者随机接受纳武利尤单抗联合铂类双药化疗或单纯铂类双药化疗,计划手术切除前接受3周期治疗。
- 支持批准的主要疗效终点为无事件生存期(EFS)。
主要发现
- 第一次计划期中分析时,EFS的HR为0.63(95%CI 0.45-0.87;P=0.0052;显著性边界=0.0262),有利于纳武利尤单抗联合化疗组。
- 纳武利尤单抗联合化疗组中位EFS为31.6个月(95%CI 30.2-未达到),单纯化疗组为20.8个月(95%CI 14.0-26.7)。
- 预设的OS期中分析时,26%的患者死亡,OS的HR为0.57(95%CI 0.38-0.87;P=0.0079;显著性边界=0.0033)。
- 纳武利尤单抗联合化疗组83%的患者接受了确定性手术,单纯化疗组为75%。
关键数值与推荐
- FDA批准纳武利尤单抗联合铂类双药化疗用于可切除NSCLC的新辅助治疗。
- EFS的HR为0.63(95%CI 0.45-0.87;P=0.0052;显著性边界=0.0262)。
- OS的HR为0.57(95%CI 0.38-0.87;P=0.0079;显著性边界=0.0033)。
临床怎么用
- 这是美国首个获批用于NSCLC新辅助治疗的方案。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: On March 4, 2022, the US Food and Drug Administration (FDA) approved nivolumab plus platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non-small-cell lung cancer (NSCLC). We discuss the FDA's review of the key data and regulatory considerations supporting this approval. PATIENTS AND METHODS: The approval was based on the results of CheckMate 816, an international, multiregional, active-controlled trial that randomly assigned 358 patients with resectable NSCLC, stage IB (≥4 cm) to IIIA (N2) per the American Joint Committee on Cancer seventh staging edition to receive either nivolumab plus platinum-doublet or platinum-doublet chemotherapy alone for three cycles before planned surgical resection. The major efficacy end point that supported this approval was event-free survival (EFS). RESULTS: At the first planned interim analysis (IA), the hazard ratio (HR) for EFS was 0.63 (95% CI, 0.45 to 0.87; P = .0052; statistical significance boundary = .0262) favoring the nivolumab plus chemotherapy arm; the median EFS was 31.6 months (95% CI, 30.2 to not reached) in the nivolumab plus chemotherapy arm versus 20.8 months (95% CI, 14.0 to 26.7) in the chemotherapy-only arm. At the time of a prespecified IA for overall survival (OS), 26% of patients had died, and the HR for OS was 0.57 (95% CI, 0.38 to 0.87; P = .0079; statistical significance boundary = .0033). Eighty-three percent of patients in the nivolumab-containing arm versus 75% in the chemotherapy-only arm received definitive surgery. CONCLUSION: This approval, the first for any regimen for the neoadjuvant treatment of NSCLC in the United States, was supported by a statistically significant and clinically meaningful improvement in EFS with no evidence of detriment in OS or negative impact on patients' receipt and timing of surgery or surgical outcomes.
引用
- Akinboro O, Drezner N, Amatya A, et al. US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer. J Clin Oncol. 2023. PMID: 37141544. doi:10.1200/JCO.22.02509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。